<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893148</url>
  </required_header>
  <id_info>
    <org_study_id>GLP1RA2021</org_study_id>
    <nct_id>NCT04893148</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes</brief_title>
  <official_title>Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes Insufficiently Controlled by Insulin Glargine and Metformin Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chungbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chungbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to compare efficacy and safety of IGlarLixi and insulin glargine plus&#xD;
      dulaglutide as intensification from basal insulin with metformin, in the absence of&#xD;
      head-to-head trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fixed-dose combinations of insulin glargine/lixisenatide (IGlarLixi) or insulin glargine plus&#xD;
      dulaglutide constitute treatment intensification in type 2 diabetes mellitus (T2D). The&#xD;
      investigators aimed to compare efficacy and safety of IGlarLixi and insulin glargine plus&#xD;
      dulaglutide as intensification from basal insulin with metformin, in the absence of&#xD;
      head-to-head trials. Treatments were compared in terms of glycated hemoglobin (HbA1c),&#xD;
      fasting plasma glucose (FPG) change from baseline, and variables from continuous glucose&#xD;
      monitoring (CGM) system; in addition to safety issues on hypoglycemia and changes in weight.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 26, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in glycated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>HbA1c will be measured at baseline and week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Comparison of FPG changes in week 12 from baseline between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose time in range (TIR)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Comparison of %TIR changes in week 12 from baseline between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose time above range (TAR)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Comparison of %TAR changes in week 12 from baseline between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose time below range (TBR)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Comparison of %TBR changes in week 12 from baseline between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Comparison of the incidence of hypoglycemia between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in weight</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Comparison of weight changes in week 12 from baseline between the two</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Glucose, High Blood</condition>
  <arm_group>
    <arm_group_label>iGlar/Lixi</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Switching to IGlarLixi from insulin glargine iGlar/Lixi starts with the following doses depending on the existing insulin glargine dose: 1) insulin glargine &lt;20 unit/day = iGlar/Lixi 10 unit/day, 2) insulin glargine &gt;=20 unit/day = iGlar/Lixi 20 unit/day.&#xD;
Training to increase the iGlar/Lixi dosage every 3 days to meet the target fasting blood glucose level to 80~130 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide plus insulin glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adding Dulaglutide to insulin glargine. Keep insulin glargine and dulaglutide start at 0.75 mg per week and increase to 1.5 mg per week after 1 month with evaluating compliance and tolerability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGlarLixi</intervention_name>
    <description>Changing to iGlarLixi from insulin glargine</description>
    <arm_group_label>iGlar/Lixi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Add dulaglutide to insulin glargine</description>
    <arm_group_label>Dulaglutide plus insulin glargine</arm_group_label>
    <other_name>Insulin Glargine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  Patient with type 2 diabetes, treated with basal insulin plus metformin (maximum&#xD;
             tolerated dosage) for at least 12 weeks&#xD;
&#xD;
          -  Patient accepting to participant to this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  severe renal dysfunction (eGFR &lt;60 ml/min/1.73m2)&#xD;
&#xD;
          -  chronic or acute hepatic disorder (HBV or HCV hepatitis, liver cirrhosis etc.)&#xD;
             (AST/ALT &gt; 2.5*ULN)&#xD;
&#xD;
          -  Prescription such as immunosuppressant agents, glucocorticoids&#xD;
&#xD;
          -  Active anti-cancer treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eu Jeong Ku, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheonju</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chungbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Eu Jeong Ku</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>IGlarLixi</keyword>
  <keyword>Dulaglutide</keyword>
  <keyword>Continuous glucose monitoring system</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

